A method of treating a disorder or a disease selected from rheumatoid arthritis (RA), pemphigus vulgaris (PV), endemic form of Brazilian pemphigus (Fogo selvagem), idiopathic thrombocytopenia purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune hemolytic anemia (AIHA), acquired hemophilia type A (AHA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), myasthenia gravis (MG), Sjögren's syndrome (SS), ANCA-associated vasculitides, cryoglobulinemia, chronic autoimmune urticaria (CAU), allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), goodpasture's syndrome, transplant rejection, cancers of haematopoietic origin, severe and cerebral malaria, trypanosomiasis, leishmaniasis, toxoplasmosis and neurocysticercosis comprising administering to a subject a therapeutically effective amount of a compound according Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein
- Y is selected from O or NH;
- V is selected from CR5 or N;
- W is selected from CH2, or O;
- U is selected from N or CH;
- Q is selected from N or CR6;
- wherein U and Q are not both N;
- R1 is selected from phenyl, pyridyl, pyrimininyl, pyrazinyl, pyridazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, or
- —X—R4
- wherein X is selected from C(O), S(O)2 or CH2 and
- R4 is selected from C1-C8-alkyl, halo-C1-C8-alkyl, hydroxy-C1-C8-alkyl, C1-C8-alkoxy-C1-C8-alkyl, cyano-C1-C8-alkyl, N,N-di-C1-C4-alkyl-amino-C1-C8-alkyl, C1-C4-alkyl-sulfonyl-C1-C8-alkyl, phenyl, heterocyclyl, heterocyclyl-oxy, heterocyclyl-C1-C8-alkyl, C3-C12-cycloalkyl, C3-C12-cycloalkyl-oxy, C3-C12-cycloalkyl-C1-C8-alkyl, heteroaryl, heteroaryl-oxy, heteroaryl-C1-C8-alkyl, hydroxy, C1-C8-alkoxy, amino, N—C1-C8-alkyl-amino or N,N-di-C1-C8-alkyl-amino,
- wherein C1-C8-alkyl in N—C1-C8-alkyl-amino and in N,N-di-C1-C8-alkyl-amino may be unsubstituted or substituted by halogen, hydroxy or C1-C4-alkoxy,
- wherein C3-C12-cycloalkyl in C3-C12-cycloalkyl and in C3-C12-cycloalkyl-C1-C8-alkyl may be unsubstituted or substituted by 1-5 substituents selected from halogen, hydroxy or C1-C4-alkoxy;
- wherein ‘heterocyclyl’ is a 3 to 7 membered saturated or partially unsaturated monocyclic ring system containing 1 to 3 heteroatoms selected from N, O or S, each of which is unsubstituted or substituted by 1-5 substituents selected from oxo, halogen, C1-C8-alkyl, halo-C1-C8-alkyl, hydroxy-C1-C8-alkyl, hydroxyl, C1-C8-alkoxy, C1-C8-alkoxy-C1-C8-alkyl, amino, N—C1-C8-alkyl-amino, N,N-di-C1-C8-alkyl-amino, C1-C8-alkyl-carbonyl, halo-C1-C8-alkyl-carbonyl, hydroxy-C1-C8-alkyl-carbonyl or C1-C8-alkoxy-C1-C8-alkyl-carbonyl;
- wherein ‘heterocyclyl’ can be attached at a heteroatom or a carbon atom and where the N and/or S heteroatoms can also optionally be oxidized to various oxidation states,
- wherein ‘heteroaryl’ is a 3 to 7 membered fully unsaturated monocyclic ring system containing 1 to 3 heteroatoms selected from N, O or S, or pyrazolo[1,5-a]pyrimidine or imidazo[2,1-b]thiazole, each of which is unsubstituted or substituted by 1-5 substituents selected from halogen, C1-C8-alkyl, halo-C1-C8-alkyl, hydroxy-C1-C8-alkyl, hydroxyl, C1-C8-alkoxy, C1-C8-alkoxy-C1-C8-alkyl, amino, N—C1-C8-alkyl-amino, N,N-di-C1-C8-alkyl-amino, C1-C8-alkyl-carbonyl, halo-C1-C8-alkyl-carbonyl, hydroxy-C1-C8-alkyl-carbonyl or C1-C8-alkoxy-C1-C8-alkyl-carbonyl;
- wherein ‘heteroaryl’ can be attached at a heteroatom or a carbon atom and where the N and/or S heteroatoms can also optionally be oxidized to various oxidation states;
- R6 is selected from hydrogen, halogen, C1-C4-alkyl, halo-C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkyl-sulfonyl, C1-C4-alkyl-sulfinyl, C1-C4-alkyl-sulfanyl, halo-C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl, amino, N—C1-C8-alkyl-amino, N,N-di-C1-C8-alkyl-amino;
- R7 is selected from hydrogen, halogen, cyano, nitro, C1-C4-alkyl, halo-C1-C4-alkyl, C1-C4-alkoxy, N(R8)2-sulfonyl, C1-C4-alkyl-sulfonyl, C1-C4-alkyl-sulfonyl-amino, C1-C8-alkoxy-C1-C8-alkyl, amino, N—C1-C8-alkyl-amino, or N,N-di-C1-C8-alkyl-amino;
- or R6 and R7, together are CH═CH—CH═CH,
- wherein R8 is independently selected from hydrogen, C1-C4-alkyl, C1-C4-alkoxy or two R8 together with the nitrogen they are attached to form a 4 to 7 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O, S, which is unsubstituted or substituted by 1-3 substituents selected from C1-C4-alkyl;
- R5 is independently selected from H, D, F or C1-C2-alkyl;
- R30 is independently selected from H, D or F.